news
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
List view / Grid view
Type 1 Diabetes
Filter the results
news
Insulin supply chain transparency needed to prevent price hikes
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
news
BCG vaccine leads to long-term blood sugar improvement in type 1 diabetes
A study has found a novel mechanism underlying stable, durable blood sugar control...
news
EMA accepts Marketing Authorisation Variation for Forxiga in adults with type-1 diabetes
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes...
news
Drug-delivering capsules could sustain transplanted insulin-producing cells
A drug-carrying microsphere within a cell-bearing microcapsule could be the key to transplanting insulin-secreting pig pancreas cells into human patients...
news
Removable implant may control type 1 diabetes
Researchers have devised a method for implanting islet cells into a patient that may control the management of type 1 diabetes...
news
FDA approves Admelog, the first follow-on insulin product to treat diabetes
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
news
Type 2 diabetes drug provides significant benefits to type 1 diabetic patients
A study has found that a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels...
article
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
news
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…